Key News
1. 2.3099 million new A-share accounts were opened in October, bringing the cumulative total for the first 10 months to 22.4588 million, a year-on-year increase of 11%.
2. The People's Bank of China: It will conduct 700 billion yuan of outright reverse repurchase operations on November 5th, with a term of 3 months (91 days).
Individual Stock News
1. Midea Group: Has cumulatively paid 9.575 billion yuan to repurchase A-shares.
2. Foxconn Industrial Internet: As of October 31st, it had cumulatively repurchased 0.04% of its shares, amounting to 147 million yuan.
3. Fuyao Glass: The legal representative of the company has changed from Cao Dewang to his son, Cao Hui.
4. Mi Holdings: The seal for the cooling salt circulation pump has been applied to the Gansu thorium-based nuclear reactor project.
5. Zhongjing Technology's third-largest shareholder, LONGi Green Energy, and director Guo Bingjian plan to reduce their holdings by no more than 3.66% in total.
6. Redick: Plans to acquire a 20.41% stake in Aoyi Technology, a robotics and brain-computer interface company, for RMB 160 million.
7. China Cinda, the third largest shareholder of Founder Securities, plans to reduce its holdings in the company by no more than 1%.
8. Trina Solar: Signed a memorandum of understanding with Pacific Green for a 5GWh grid-scale battery energy storage system.
9. Baili Tianheng: Its innovative biological drug T-Bren (HER2ADC) has been included in the list of breakthrough therapies.
10. Baose: Not involved in the 2MWt liquid fuel thorium-based molten salt experimental reactor (TMSR-LF1) project reported by the media.
11. Hailu Heavy Industry: The safety dedicated device for the 2MWt liquid fuel thorium-based molten salt experimental reactor manufactured by the company passed the acceptance review by the expert group of the Chinese Academy of Sciences.
12. Lanzhou Petrochemical Equipment: Only microchannel heat exchangers and plate heat exchangers in the company's business have relevant applications in the field of controlled nuclear fusion.
13. Tianpu Pharmaceutical: The share transfer agreement signed between the controlling shareholder and its concerted parties and Zhonghao Xinying has been completed.
14. Haichuang Pharmaceutical: The first batch of participants have been enrolled in the Phase II clinical trial of its drug HP515 for the treatment of metabolic-related steatohepatitis. Currently, there are no similar target products approved for marketing in China.
